Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Semisynthesis, characterisation, and antibacterial evaluation of a novel lecanoric acid-derived amide library.

Beilstein journal of organic chemistry·2026
Same author

Anti-invasive and cytotoxic evaluation of a (+)-pinoresinol-based semisynthetic library against glioblastoma.

Beilstein journal of organic chemistry·2026
Same author

Genetic association between SORBS1 rs2274490 and INSR rs12971499 polymorphisms with polycystic ovary syndrome: A case-control study.

Journal of education and health promotion·2026
Same author

Total Syntheses of Roseochelins A and B Using an Oxidative Decarboxylation Strategy.

Organic letters·2026
Same author

TiO₂ nanotube-supported Cu(II)-Schiff base complex as an efficient heterogeneous catalyst for A³ coupling reactions under solvent-free conditions.

Scientific reports·2026
Same author

Analytical Techniques in Label-Free Detection of Cancer Diagnosis.

Critical reviews in analytical chemistry·2025

Related Experiment Video

Updated: Jul 4, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Rationally designed copper-deferiprone-phenanthroline complex as a dual anticancer and SARS-CoV-2 inhibitor.

Zeinab Mirzaei-Kalar1, Ali Akbar Khandar1, Jonathan M White2

  • 1Department of Inorganic Chemistry, Faculty of Chemistry, University of Tabriz Tabriz 51666-14766 Iran mirzaei.zeynab@yahoo.com akhandar@yahoo.com +98-4133340191 +98-4133393125.

RSC Advances
|July 3, 2026
PubMed
Summary

A novel copper complex shows potent anticancer activity against multiple cancer cell lines and inhibits SARS-CoV-2 targets. This dual-action agent offers a promising therapeutic strategy for both cancer and viral infections.

More Related Videos

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach
10:01

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach

Published on: June 23, 2026

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Published on: September 17, 2019

Related Experiment Videos

Last Updated: Jul 4, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach
10:01

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach

Published on: June 23, 2026

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Published on: September 17, 2019

Area of Science:

  • Materials Chemistry
  • Medicinal Chemistry
  • Molecular Biology

Background:

  • Deferiprone and phenanthroline are known chelating agents with therapeutic potential.
  • Copper complexes have demonstrated diverse biological activities, including anticancer properties.
  • There is a need for novel therapeutic agents with dual anticancer and antiviral activities.

Purpose of the Study:

  • To design, synthesize, and characterize a novel ternary copper-deferiprone-phenanthroline complex.
  • To investigate the DNA binding modes and cytotoxic effects of the complex against human cancer cell lines.
  • To evaluate the complex's potential as an inhibitor of SARS-CoV-2 targets.

Main Methods:

  • Synthesis and characterization of the copper complex.
  • DNA interaction studies (groove binding vs. intercalation).
  • Cytotoxicity assays (HT-29, HepG2, MDA-MB-468, HEK-293), flow cytometry, gene expression analysis (BCL2, BAX, Caspase-3), and molecular docking simulations.

Main Results:

  • The copper complex exhibited preferential DNA intercalation and potent cytotoxicity against cancer cells with lower toxicity to normal cells.
  • The complex induced late-stage apoptosis and G1-phase cell cycle arrest, confirmed by gene expression changes.
  • Molecular docking revealed strong binding affinities to key SARS-CoV-2 proteins (Mpro, PLpro, RdRp, N-terminal domain), outperforming existing antiviral agents.

Conclusions:

  • The copper-deferiprone-phenanthroline complex is a promising dual-action agent with significant anticancer and potential antiviral (SARS-CoV-2) properties.
  • Its mechanism involves DNA intercalation, apoptosis induction, and cell cycle arrest.
  • Further investigation is warranted for its development as a therapeutic candidate for cancer and viral diseases.